Inorganic Active Ingredients TRIZ Cases

Multiple stem cell-derived components and natural compounds address Long COVID symptom severity through adaptable treatment routes.

This case uses an acidified liquid NORS to deliver quick, prolonged nitric oxide release without continuous gas-cylinder connection.

This case uses nitrite and an acidifying agent to release nitric oxide over time, supporting ambulatory treatment of wounds and infections.

Local nasal nAChR agonists target respiratory coronavirus infection with less systemic exposure.

A pressure-controlled vapor assembly creates supersaturated dissolved gas for continuous transdermal delivery of agents over 500 Daltons.

Combining ginger extract with a lithium source addresses poor solubility and supports improved bioavailability in nutraceuticals.

This case combines CDK inhibition with redox control to raise ROS in cancer cells, promote apoptosis, and limit drug resistance.

GR and ER profiling identifies high-risk breast cancer and guides antagonist combinations to address chemotherapy resistance.

This case combines 12 traditional Chinese medicine ingredients as a suppository or powder spray to address pain and bleeding.

This case addresses low-energy, therapist-dependent scalar-wave devices with a portable generator using stone, sand, metal, and water.

This case combines an ammonium sulfate liposome with a platinum preparation to improve drug retention, tumor release, and safety.

This case uses ionic zinc and alkyl glycoside to limit aggregation while preserving rapid insulin action in high-concentration pens.

This case uses zinc carbonate hydroxide with controlled dissolution and pH to support bone repair while minimizing residue.

Folate-targeted Zn(II)/γ-PGA compositions induce PARP1-mediated necrosis while limiting stomach dissociation and systemic toxicity.

This case combines LOH, TAI, and LST chromosomal aberration scores to assess HRD and guide personalized cancer treatment selection.

This case uses sonicated ceramic and a flow-through column to alter water structure for aquaporin transport and metabolic waste removal.

This case uses gamma polyglutamated methotrexate in liposomes to improve cancer-cell delivery and address toxicity and resistance.

MnO2 structures combined with ECM proteins form a biodegradable porous scaffold that supports stem cells and limits burst release.

ERCC1-XPF inhibitors sensitize cancer cells to cisplatin while limiting toxicity.

This case quantifies LOH region number and size to identify HDR-deficient cancers and predict response to PARP inhibitors and other agents.

Structure-based inhibitors target ERCC1-XPF to limit off-target DNA repair effects.